Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
11/06/2018
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C.
Descargar documento
Arch Dermatol. 2012 Apr;148(4):463-70. PubMed PMID: 22508869